학술논문

Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1).
Document Type
Article
Source
Investigational New Drugs; Aug2020, Vol. 38 Issue 4, p1117-1128, 12p
Subject
ANTINEOPLASTIC agents
CANCER patients
CLINICAL trials
DRUG tolerance
DRUG side effects
DRUG toxicity
ENZYME inhibitors
PACLITAXEL
PATIENT safety
TUMORS
TREATMENT effectiveness
CARBOPLATIN
Language
ISSN
01676997
Abstract
Copyright of Investigational New Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)